Drug intelligence / Profile preview

Myr5A

Development stage: Preclinical
Lead developer: Qana Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Parenteral

Overview

Myr5A is a targeted lipid nanoparticle (LNP) delivery system developed by Qana Therapeutics for the treatment of rare pediatric and adolescent cancers, specifically Ewing sarcoma and Desmoplastic Small Round Cell Tumor (DSRST). The platform is designed to selectively deliver therapeutic payloads to tumor cells, aiming to enhance efficacy while reducing systemic toxicity. As of 2023, Myr5A is in preclinical development, with studies conducted at Emory University in collaboration with Dr. Jason Yustein's laboratory and supported by funding from the Rutledge Cancer Foundation. It is being investigated as a component of a combination therapy approach alongside two other undisclosed therapies.

Targets

SCARB1 (Scavenger receptor class B member 1)

Beyond the preview

Go deeper on Myr5A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myr5A.

Explore the full profile